Cost effectiveness of first-line daratumumab in MM, base-edited CAR T cells for T-ALL, and the role of SETBP1 mutations in chronic neutrophilic leukemia

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

The Ezra Klein Show: Jensen Huang Thinks A.I. Alarmism Has Gone Too Far 1h 50m · 25 Sep 2026 · Hard Fork

Pretty Little Episode #110 26 min · 25 Sep 2026 · Handsome

Be Upfront About How You Make Money From Your Podcast 2 min · 25 Sep 2026 · One Minute Podcast Tips - Be a Better Podcaster in Just 60 Seconds

High Stakes US-China Sit Down & Flock Surveillance Under Scrutiny | 9.25.26 19 min · 25 Sep 2026 · Morning Wire

Trump Spooked by Plane at Xi Meeting & Sen. Tuberville Rails Against Flying Furries | Merritt Wever 37 min · 25 Sep 2026 · The Daily Show: Ears Edition

Ireland collapse in Kosovo as Israel game looms 13 min · 25 Sep 2026 · Today with David McCullagh

Report any issue

Source

Recorded11 Aug 2022

Publisherfeeds.transistor.fm ↗

Handlerec:11742074

Show notes

In this week’s episode new research suggesting that, in patients with transplant-eligible multiple myeloma, adding daratumumab to first-line combination regimens may be a more cost effective strategy than saving it for second-line use. We’ll also review the work of researchers who applied base-editing technology to develop a complex and potent CAR T cell product for potential “off-the-shelf” use in patients with T-cell leukemias and other CD7-positive malignancies. Finally, we’ll review a paper that elucidates the role of SETBP1 mutations in chronic neutrophilic leukemia, pointing the way toward a potential multi-pronged therapeutic approach to this rare myeloproliferative neoplasm.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in